2023
Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing.
Giri V, Keith S, Cheng H, Leader A, Gross L, Sanchez Nolasco T, Byrne N, Hartman R, Brown L, Pieczonka C, Gomella L, Kelly W, Lallas C, Handley N, Mille P, Mark J, Brown G, Chopra S, McClellan A, Loeb S. Technology-enhanced acceleration of germline evaluation for therapy (TARGET): Results of a randomized controlled trial of a pretest patient-driven webtool vs. genetic counseling for prostate cancer germline testing. Journal Of Clinical Oncology 2023, 41: 10598-10598. DOI: 10.1200/jco.2023.41.16_suppl.10598.Peer-Reviewed Original ResearchDecisional conflictGenetic testingPre-test genetic counselingGermline testingGenetic counselingProstate cancerRandomized non-inferiority trialHereditary cancer risk assessmentGermline genetic testingClinical trial eligibilityNon-inferiority trialProstate Cancer FoundationProstate cancer managementCancer genetic testingDecision Conflict ScaleCancer risk assessmentGermline evaluationTrial eligibilityPrimary endpointMean ageStudy protocolCancer managementGenetics educationAnalysis of covarianceCancer Foundation
2022
Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study.
Giri V, Gross L, Russo J, Shimada A, McNair C, Kelly W, Gomella L. Prevalence of Fanconi anemia gene mutations among men undergoing multigene germline testing for prostate cancer: Interim results from the EMPOWeR study. Journal Of Clinical Oncology 2022, 40: 188-188. DOI: 10.1200/jco.2022.40.6_suppl.188.Peer-Reviewed Original ResearchProstate cancerPrevalence of FAGermline testingEMPOWER studyMultigene testingMutation carriersMutation prevalencePopulation prevalenceExact testLimited prevalence dataGene mutationsLikely pathogenic mutationsFisher's exact testCancer risk genesClinical characteristicsGleason scoreMean ageClinical trialsPCa diagnosisFA genesFas gene mutationPrevalence ratesCancer managementPCa biologyFA pathway genes
2020
Exploring African American males' attitudes towards genetic testing for prostate cancer risk.
Leader A, Fortune T, Weddington P, Crumpler N, Giri V. Exploring African American males' attitudes towards genetic testing for prostate cancer risk. Journal Of Clinical Oncology 2020, 38: e13552-e13552. DOI: 10.1200/jco.2020.38.15_suppl.e13552.Peer-Reviewed Original ResearchFamily historyGenetic testingAA malesAA menHigher prostate cancer incidencePrimary care visitsProstate cancer incidenceGenetic counselingImportant risk factorProstate cancer riskHealth history informationFocus groupsFamily health historyCare visitsMean ageCancer incidenceRisk factorsCancer riskMortality rateHealth historyLow-resource neighborhoodsCare limitationsInformed consentMost menAfrican American males